| 1 |
Review The role of CETP inhibition in dyslipidemia. 2007
El Harchaoui K, van der Steeg WA, Stroes ES, Kastelein JJ. · Department of Vascular Medicine, Academic Medical Centre, University of Amsterdam, Room F4-159.2, Meibergdreef 9, Postbus 22660, 1105 AZ Amsterdam, The Netherlands. · Curr Atheroscler Rep. · Pubmed #17877921 No free full text.
Abstract: Cholesteryl ester transfer protein (CETP) inhibitors are currently being investigated because of their ability to increase high-density lipoprotein cholesterol levels. In various metabolic settings, the relationship between CETP and lipoprotein metabolism is complex and may depend largely on the concentration of triglyceride-rich lipoproteins. Two CETP inhibitors, JTT-705 and torcetrapib, are in an advanced phase of development. Following hopeful intermediate results, a large endpoint study using torcetrapib has just been discontinued due to increased mortality in torcetrapib-treated subjects. In this review we summarize clinical data on the use of CETP inhibitors.
|